ArticleJournal of translational medicine2011
SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: online resources and useful tools - a compass in the land of biomarker discovery.
Article in Journal of translational medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Immunotherapy with cancer peptides in combination with intravesical bacillus Calmette-Guerin for patients with non-muscle invasive bladder cancer.Cancer immunology, immunotherapy : CII · 2018Trial
- Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens.Journal of translational medicine · 2012Trial
- Evaluation of SLOG/TCI-III pediatric system on target control infusion of propofol.Journal of translational medicine · 2011Trial
- Optimizing Anti-PD1 Immunotherapy: An Overview of Pharmacokinetics, Biomarkers, and Therapeutic Drug Monitoring.Cancers · 2025Review
- Urinary miRNAs: Technical Updates.MicroRNA (Shariqah, United Arab Emirates) · 2024Review
- SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery.Journal for immunotherapy of cancer · 2020Article
- The Society for Immunotherapy of Cancer Biomarkers Task Force recommendations review.Seminars in cancer biology · 2018Review
- Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy.Journal of hematology & oncology · 2016Review
- Checkpoint Inhibitors and Their Application in Breast Cancer.Breast care (Basel, Switzerland) · 2016Review
- Immune cell impact of three differently coated lipid nanocapsules: pluronic, chitosan and polyethylene glycol.Scientific reports · 2016Article
- Preamble to the 2015 SITC immunotherapy biomarkers taskforce.Journal for immunotherapy of cancer · 2015Article
- The immune-related role of BRAF in melanoma.Molecular oncology · 2015Article
- Impact of carbon nanotubes and graphene on immune cells.Journal of translational medicine · 2014Review
- Application of carbon nanotubes layered on silicon wafer for the detection of breast cancer marker carbohydrate antigen 15-3 by immuno-polymerase chain reaction.Journal of materials science. Materials in medicine · 2014Article
- CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2.British journal of cancer · 2013Article
- Serum-free freezing media support high cell quality and excellent ELISPOT assay performance across a wide variety of different assay protocols.Cancer immunology, immunotherapy : CII · 2013Article
- Ipilimumab: its potential in non-small cell lung cancer.Therapeutic advances in medical oncology · 2012Article
- Muscle CARs and TcRs: turbo-charged technologies for the (T cell) masses.Cancer immunology, immunotherapy : CII · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Recent positive clinical results in cancer immunotherapy point to the potential of immune-based strategies to provide effective treatment of a variety of cancers. In some patients, the responses to cancer immunotherapy are durable, dramatically extending survival. Extensive research efforts are being made to identify and validate biomarkers that can help identify subsets of cancer patients that will benefit most from these novel immunotherapies. In addition to the clear advantage of such predictive biomarkers, immune biomarkers are playing an important role in the development, clinical evaluation and monitoring of cancer immunotherapies. This Cancer Immunotherapy Resource Document, prepared by the Society for Immunotherapy of Cancer (SITC, formerly the International Society for Biological Therapy of Cancer, iSBTc), provides key references and online resources relevant to the discovery, evaluation and clinical application of immune biomarkers. These key resources were identified by experts in the field who are actively pursuing research in biomarker identification and validation. This organized collection of the most useful references, online resources and tools serves as a compass to guide discovery of biomarkers essential to advancing novel cancer immunotherapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.